Articles Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial

Summary Background Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in combination with other antiemetic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy in adults, but its effi cacy and safety in paediatric patients are unknown. We did this phase 3 trial to examine the safety and effi cacy of such treatment in children

Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects

Background/purpose: This multicenter, randomized, partially-blinded phase IIb study evaluated the pharmacokinetics (PK)/pharmacodynamics, safety, and tolerability of aprepitant in pediatric subjects for the prevention of postoperative nausea and vomiting (PONV)